4Q Revenues: $14.8 billion (flat)
4Q Earnings: $2.1 billion (+72%)
YTD Revenues: $56.7 billion (-3%)
YTD Earnings: $9.6 billion (+4%)
Comments: Pharmaceutical sales were flat at $8.3 billion in the quarter. Products launched since 2007 generated $3.1 billion or 38% of sales, up 26%, offsetting the loss of exclusivity for Diovan HCT in the U.S. Alcon sales were up 6% to $2.6 billion, with the Surgical franchise up 8%, Ophthalmic Pharmaceuticals up 5%, and Vision Care up 4%. Sandoz sales grew 4% to $2.4 billion, with Fougera contributing 7% of the growth from four months of sales. Vaccines and Diagnostics sales of were $628 million, down 6%. Consumer Health, which includes OTC and Animal Health, declined 11% to $961 million, impacted by the continuing absence of shipments from the Lincoln, NE manufacturing site. Charges in 2011 included $1.0 billion, primarily $0.9 billion related to Tekturna/Rasilez.